key: cord-0297195-im8jg60m authors: Bamford, Connor G. G.; Broadbent, Lindsay; Aranday-Cortes, Elihu; McCabe, Mary; McKenna, James; Courtney, David; Touzelet, Olivier; Ali, Ahlam; Roberts, Grace; Lopez Campos, Guillermo; Simpson, David; McCaughey, Conall; Fairley, Derek; Mills, Ken; Power, Ultan F. title: Collaboration Between Host and Viral Factors Shape SARS-CoV-2 Evolution date: 2021-07-16 journal: bioRxiv DOI: 10.1101/2021.07.16.452629 sha: 44479c16a33a75162744465ad4fcbbaca100bab8 doc_id: 297195 cord_uid: im8jg60m SARS-CoV-2 continues to evolve, resulting in several ‘variants of concern’ with novel properties. The factors driving SARS-CoV-2 fitness and evolution in the human respiratory tract remain poorly defined. Here, we provide evidence that both viral and host factors co-operate to shape SARS-CoV-2 genotypic and phenotypic change. Through viral whole-genome sequencing, we explored the evolution of two clinical isolates of SARS-CoV-2 during passage in unmodified Vero-derived cell lines and in parallel, in well-differentiated primary nasal epithelial cell (WD-PNEC) cultures. We identify a consistent, rich genetic diversity arising in vitro, variants of which could rapidly rise to near-fixation with 2 passages. Within isolates, SARS-CoV-2 evolution was dependent on host cells, with Vero-derived cells facilitating more profound genetic changes. However, most mutations were not shared between strains. Furthermore, comparison of both Vero-grown isolates on WD-PNECs disclosed marked growth attenuation mapping to the loss of the polybasic cleavage site (PBCS) in Spike while the strain with mutations in NSP12 (T293I), Spike (P812R) and a truncation of ORF7a remained viable in WD-PNECs. Our work highlights the significant genetic plasticity of SARS-CoV-2 while uncovering an influential role for collaboration between viral and host cell factors in shaping viral evolution and fitness in human respiratory epithelium. To begin to understand the evolution of SARS-CoV-2 we first 127 needed to generate characterised stocks of virus (Fig 1A) . In the first grew efficiently, reaching titres of >10 6 pfu/mL (Fig 1B) and was 138 cytopathic, inducing 'webbing' and cell rounding, consistent with previous 139 reports (data not shown). 140 As we wanted to understand the viral factors that may drive 141 evolution and results obtained from only one isolate may be non-142 representative, we next obtained an independent -but comparable -143 clinical nasal/pharyngeal swab sample containing SARS-CoV-2, which we 144 termed BT20.1 (Belfast 06/20). This strain represents an isolate from the 145 UK's 'first wave' and is a representative of clade B that contains the 146 D614G mutation in Spike (table 1) . Unlike PHE, BT20.1 was isolated on 147 standard Vero cells (CCL-81) and passaged to P4 (multiplicity of infection 148 Comparison of SARS-CoV-2 evolution in vitro during passage in Vero and primary human airway cells 6 [MOI]~0.001 and passaged every 3 days). Like PHE, BT20.1 grew 149 efficiently, reaching titres of >10 6 pfu/mL (Fig 1B) . 150 Both PHE and BT20.1 formed plaques on standard Vero cells in all 151 passages (Fig 1C and D) . Comparison of plaque sizes between P2 and P4 152 identified differences in plaque size composition following Vero cell 153 passage. This was most evident for PHE, which became predominantly 154 large plaques (Fig 1 E and F) . As observed in the plaque edge, BT20.1 155 induced consistent cell-to-cell fusion, unlike PHE (sFig 1 A and B) . Schematic of SARS-CoV-2 isolation/serial passage series on VeroE6 or Vero cells for PHE 160 and BT20.1 from isolation to P4 (a). Extracellular infectivity titres for stocks generated 161 from P2-P4 VeroE6/Vero passage for PHE and BT20.1 using plaque assay protocol on Sequencing of SARS-CoV-2 passage series in unmodified Vero- 166 derived cells 167 As we had successfully generated comparable in vitro passage table 1) . Unfortunately, the sequence depth and 175 quality were not sufficient to reconstruct a whole genome sequences for 176 BT20.1 P1 isolate material, likely due to insufficient viral material 177 resulting from the initial isolation. Therefore, we focused our analysis on 178 PHE P1-4 and BT20.1 P2-P4. Analysing mutations in the PHE passage series we identified 4 180 changes (C8782T; T18488T; T28144C; A29596G) relative to Wuhan-Hu-1 181 consistently at ~100% at all passages, likely reflecting fixation in the 182 original virus stock (Fig 2A) [I]) mapping to the polybasic cleavage site (PBCS) (Fig 2A) . (supplementary table 1) . 210 Like PHE, we identified core changes inherent to BT20.1 (Fig 2B) , 211 which were greater in number than PHE (10 vs 4), consistent with its later 212 isolation (February 2020 versus June 2020) (supplementary also detected minor variants (9), including G1251V and S1252C in Spike. Passage of SARS-CoV-2 on primary human airway cultures 234 We next sought to investigate the effect of host cell type on differences between viral sub-clones (Fig 1 E and F) . We detected an in- PNECs, respectively, relative to the reference sequence (Wuhan-Hu-1). Only sequences from P1-P4 (PHE) and P2-P4 (BT20.1) were analysed. Public Health England and Professor Maria Zambon for the original SARS-697 England 02/20 isolate; Belfast Health and Social Care Trust for the 698 original SARS-CoV-2 clinical material from which BT20.1 was derived Professor Alain Kohl (MRC-University of Glasgow Centre for Virus 700 Research) for the VeroE6 cells; and Dr Suzannah Rihn Glasgow Centre for Virus Research) for the VeroE6 cells expressing 702 human ACE2 and human TMPRSS2; QUB staff Mervyn McCaigue Paul Crowe and Zoe Hunter for 704 their assistance in establishing and maintaining the QUB SARS-CoV-2 705 BSL3 facility; and finally, Professor Jose Bengoechea for unwavering 706 support for QUB virology at this critical time. We also wish to thank the 707 QUB Genomics Core Technology Unit for their help with sequencing Funding from UKRI/NIHR (MC_PC_19057) to UP, KM; PHA HSCNI R&D Evolutionary origins of the SARS-CoV-2 sarbecovirus 718 lineage responsible for the COVID-19 pandemic COVID-19 pandemic-a focused review 721 for clinicians A neutralizing human antibody binds to the N-terminal 726 domain of the Spike protein of SARS-CoV-2 Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell 731 passage induced in-frame deletion of the furin-like cleavage site from the spike 732 glycoprotein A Replication-Competent Vesicular Stomatitis 738 Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition The Galaxy platform for accessible, reproducible and 744 collaborative biomedical analyses Dexamethasone in Hospitalized Patients with Covid-19 Relative Respiratory Syncytial Virus 751 Cytopathogenesis in Upper and Lower Respiratory Tract Epithelium SARS-CoV-2 variants, spike 757 mutations and immune escape Structure of replicating SARS-CoV-2 polymerase A Multibasic Cleavage Site in 763 the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells COVID-19: 768 public health management of the first two confirmed cases identified in the UK SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the 774 Respiratory Tract Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production Loss of furin cleavage site attenuates SARS-CoV-2 783 pathogenesis SARS-CoV-2 growth, furin-788 cleavage-site adaptation and neutralization using serum from acutely infected 789 hospitalized COVID-19 patients SARS-CoV-2 vaccines in development Human airway cells prevent sars-cov-2 multibasic cleavage site cell culture 796 adaptation. ELife, 10 Nsp3 of coronaviruses: Structures and 798 functions of a large multi-domain protein Genomic characterisation and epidemiology of 2019 novel 803 coronavirus: implications for virus origins and receptor binding. The Lancet Freely accessible 808 ready to use global infrastructure for SARS-CoV-2 monitoring Enhanced isolation 813 of SARS-CoV-2 by TMPRSS2-expressing cells SARS-CoV-2 genomic surveillance identifies naturally occurring truncation 818 of ORF7a that limits immune suppression SARS-coronavirus-2 replication in Vero E6 cells: Replication 823 kinetics, rapid adaptation and cytopathology The furin cleavage site in the SARS-CoV-829 2 spike protein is required for transmission in ferrets SARS-CoV-2 833 variants reveal features critical for replication in primary human cells Overcoming culture 838 restriction for SARS-CoV-2 in human cells facilitates the screening of compounds 839 inhibiting viral replication A plasmid DNA-launched SARS-CoV-2 845 reverse genetics system and coronavirus toolkit for COVID-19 research Structural basis of receptor recognition by SARS-CoV-2 Improvements to 853 the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using 854 nanopore 858 vitro modeling of respiratory syncytial virus infection of pediatric bronchial The authors would like to thank the following individuals and 695 organisations for provision of critical reagents, and technical assistance: